Medical cannabis for autism compared to standard medications: what the evidence shows

Commonly prescribed ASD medications display varying efficacy, safety, and tolerability, with some causing side effects (aggression, anxiety, irritability, cognitive effects) that mirror the very symptoms they target. CBD-rich medical cannabis appeared effective and tolerable for both core ASD symptoms and comorbidities like irritability and sleep problems in observational studies, though no placebo-controlled trials existed at the time of review.

Literature review comparing safety and efficacy profiles of medications commonly used in ASD with available evidence on medical cannabis, including biological plausibility through the endocannabinoid system.

With no FDA-approved medications for core ASD symptoms and only two approved for associated irritability, families face difficult treatment decisions. Understanding how cannabis compares to existing options is directly relevant to clinical practice.

The gap between the limited approved treatments for ASD and the growing patient interest in cannabis underscores the urgent need for controlled clinical trials comparing these options directly.

No placebo-controlled cannabis trials for ASD existed at the time of review. Observational studies have inherent biases. Long-term safety of cannabis in ASD populations is unknown. Heterogeneity of ASD makes treatment comparisons difficult.